Compare DTM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTM | MRNA |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.5B |
| IPO Year | N/A | 2018 |
| Metric | DTM | MRNA |
|---|---|---|
| Price | $120.10 | $31.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $121.92 | $33.25 |
| AVG Volume (30 Days) | 727.7K | ★ 10.4M |
| Earning Date | 10-30-2025 | 02-13-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | $1,175,000,000.00 | ★ $2,232,000,000.00 |
| Revenue This Year | $27.73 | N/A |
| Revenue Next Year | $8.54 | $2.17 |
| P/E Ratio | $30.43 | ★ N/A |
| Revenue Growth | ★ 20.39 | N/A |
| 52 Week Low | $83.30 | $22.28 |
| 52 Week High | $122.70 | $48.92 |
| Indicator | DTM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 58.27 |
| Support Level | $117.03 | $32.14 |
| Resistance Level | $121.60 | $35.90 |
| Average True Range (ATR) | 2.14 | 1.59 |
| MACD | -0.19 | 0.27 |
| Stochastic Oscillator | 65.33 | 46.75 |
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.